All In Biotech

Drug Trial Radar · NCT07436728

A Study of TAK-505 in Adults With Solid Tumors

A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

151

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Aug 18, 2030

Study completion Aug 18, 2030

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable). This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC). The main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).

Conditions

  • Malignant Solid Tumors

Interventions

  • TAK-505Drug

    Participants will receive TAK-505 intravenously (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From initial dose until 28 days after infusion of the first cohort dose on Cycle 1 Day 1
  2. Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Clinically Significant Laboratory Values and Vital SignsTime frame: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)
  3. Phase 2 Dose Expansion: Confirmed Overall Response Rate (ORR)Time frame: Up to end of study (up to approximately 52 months)
  4. Phase 2 Dose Expansion: Number of Participants With TEAEs, Clinically Significant Laboratory Values and Vital SignsTime frame: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Health

    Orange, California · Recruiting

  • University of California San Diego Medical Center, La Jolla

    San Diego, California · Not yet recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • H Lee Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Univeristy of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Mary Crowley Cancer Center

    Dallas, Texas · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

  • Seattle Cancer Care Alliance

    Seattle, Washington · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.